Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice

Hans E. JohnsenDepartment of Haematology, Aalborg Hospital, Aalborg, DenmarkCorrespondence[email protected]

Corrine HaiounHematology, Henri Mondor Hospital, Creteil, France

Pieternella J. LugtenburgDepartment of Hematology, Erasmus MC, Rotterdam, The Netherlands

Antonio SalarHematology Department, Hospital del Mar, Barcelona, Spain

Ulrich JaegerDivision of Hematology and Hemostaseology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria

Ruth PettengellHaematology, St George's University of London, London, UK

Francesca G. RossiUO Ematologia 1–CTMO, Fondazione Policlinico MaRe IRCCS, Milano, Italy

Gregor VerhoefUniversity Hospital, Leuven, Belgium

Matthias SchwenkglenksInstitute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland

Kate BendallAMLtd, London, UK

Ulrich DuehrsenDepartment of Hematology, University Hospital Essen, Essen, Germany

show all

Click to increase image sizeClick to decrease image size

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice

Information for

Open access

Opportunities

Help and information

Importance of granulocyte colony-stimulating factor prophylaxis in therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone given every 14 days for diffuse large B-cell lymphoma in routine clinical practice

Potential conflict of interest:

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature